A s bstract. Cultured fibroblasts from a recently described patient with homocystinuria and megaloblastic anemia of infancy without methylmalonic aciduria were previously shown to have normal cobalamin uptake and a specific decrease in the proportion of intracellular methylcobalamin. As in control cells but unlike in those from patients with combined homocystinuria and methylmalonic aciduria (cobalamin C and cobalamin D), accumulated 57Co-labeled cobalamin was bound in appropriate amounts and proportion to intracellular binders which are known to be the two vitamin B12-dependent enzymes, methionine synthetase and methylmalonylCoA mutase. Despite the association of a normal quantity of intracellular cobalamin with methionine synthetase, the proportion of intracellular cobalamin which was methyl-B12 was below normal and in the range observed in cobalamin C and D cells. This methyl-B12 was decreased by exposure of fibroblasts in culture to nitrous oxide as was observed with control cells. Exposure of control fibroblasts during culture, but not of fibroblasts from this patient, to nitrous oxide significantly reduced
Introduction
Inherited disorders affecting vitamin B12 include those affecting transport and those affecting intracellular metabolism. Transport defects include inherited abnormalities of gastrointestinal absorption due to either abnormal transport protein (intrinsic factor) or unexplained defects in translocation of vitamin from lumen to portal plasma. Defective transfer of vitamin B12 after absorption is caused by absent or defective transcobalamin II which facilitates entry of circulating vitamin B12 into cells.
Coenzyme forms of vitamin B12 (cobalamin) in mammalian cells have been shown to mediate enzyme reactions generating succinyl-coenzyme A from methylmalonyl-coenzyme A (reaction I), methionine from homocysteine (reaction II), and interconverting alpha and beta leucine (reaction III):
Methylmalonyl-CoA + Ado-B12 -Succinyl-CoA + Ado-B12 (I)
Homocysteine + CH3-B12 -Methionine + Blu(Co+') (II)
Leucine + Ado-B12 -Beta leucine + Ado-B12.
5' deoxyadenosyl cobalamin (Ado-B12)' which produce methylmalonic aciduria without homocystinuria (cobalamin A and B disease) and those which affect the synthesis of both ado-B,2 and methylcobalamin (CH3-B,2) which produce homocystinuria and homocystinemia without increased plasma methionine, and also produce methylmalonic aciduria with or without megaloblastic anemia (cobalamin C and D diseases).
We have recently described a patient who presented with megaloblastic anemia and homocystinuria but no methylmaionic aciduria (1) . Fibroblasts from this patient required extracellular methionine for growth, unlike normal fibroblasts which could grow on homocysteine, and had impaired incorporation of labeled methyl from 5-C113-H4PteGlu into protein, indicating defective synthesis of methionine. Unlike cells from patients with inherited defects described previously, total cobalamin incorporation was normal in these cells. Intracellular Ado-B,2 was normal but CH3-Bl2 was decreased. Despite evidence of defective synthesis of methionine within intact cells, methionine synthetase (5-methyltetrahydropteroyl-L-glutamate:L-homocysteine S-methyltransferase; E.C. 2.1.1.13) activity assayed in cell extracts was normal. The present studies suggest that this patient has an abnormality of methionine biosynthesis in vivo which is overcome in the standard assay procedure for methionine synthetase. This defect is probably due to failure of reduction of B,2 bound to methionine synthetase.
Methods
Materials. Tissue culture medium was purchased from Flow Laboratories (Rockville, MD). Folate-and methionine-deficient medium was purchased from Grand Island Biological Co. (Grand Island, NY).
['4C]methyltetrahydrofolate (CH3HPteGlu) (5, 6) . Routinely, the medium contained 10% fetal calf serum, dialyzed where indicated against a 10-fold excess of 0.9% NaCI with two changes. For cobalamin uptake experiments using [57Co]CN-B,2, medium contained 10% human serum which had been preincubated with labeled CN-B12 as described by Mellman et al. (2) . All cultures containing cobalamin derivatives were both incubated and harvested in the dark. Cells were released from the culture vessels by exposure to 0.25% trypsin for 10 min at 370C and resuspended in phosphate-buffered saline (pH 7.4), and an aliquot was removed for enumeration in a Coulter counter (Coulter Electronics, Hialeah, FL). The cell pellet was washed twice in phosphatebuffered saline and collected by centrifugation.
Assay of methionine synthetase activity. Confluent fibroblasts, cultured as described above were resuspended at a final concentration of 10' cells/ml in 0.1 M potassium phosphate (pH 7.4). The cell suspension was sonicated on ice using four 20-s blasts with intervals of 20 s between blasts. The sonicates were centrifuged for 10 min X 48,000 g and the supernatant used. This supernatant has been designated as "cell extract" or "extract." Assay of the methionine synthetase activity was performed essentially according to the method of Mellman et al. (2) . In a total volume of 0.2 ml, the reaction mixture (8) in complete darkness in 10 ml of absolute ethanol at 850C for 20 min and centrifuged, and 8 ml of supernatant ethanol was evaporated to dryness under a stream of nitrogen at room temperature. The dry residue was dissolved in 1 ml of water and mixed with 10 ml of ether followed by separation of ether by centrifugation. 8 ml of separated ether was discarded, and the remainder evaporated under a stream of nitrogen gas at room temperature. The remaining 1 ml aqueous sample was applied to a column of SP Sephadex C-25 (35 X 1.6 cm) (9) . 30 3.5-ml fractions were eluted with water followed by 30 fractions eluted with 0.05 M sodium acetate, pH 5, and 40 fractions eluted with 0.1 N NaOH to strip the column. When standards of CN-BI2, OH-B12, CH3-BI2, and Ado-B12 were so treated and fractionated, they were eluted in fractions 10-12, 14-18, 45-55, and 69-80, respectively.
Following completion of most of the fractionations described here, some were reanalysed on high pressure liquid chromatography using a Merck column Lichrosorb RP-8 (E. Merck, Darmstadt, West Germany), 10 um eluted with a gradient of phosphate at pH 3 and triethylammonium phosphate as described by Jacobsen et al. (10) . For high pressure liquid chromatography fractionation, extraction was identical to that above except that extraction with ether was omitted.
Results
Accumulation and distribution oflabeled cobalamin by mutant cells. As reported previously, accumulation of label from [5" Co]CN-BI2 in culture medium over 4 d was equal in cells of the patient and normal cells, whereas the previously described defective accumulation of cobalamin by fibroblasts from patients with cobalamin C and D disease was observed. The majority of label associated with normal and patient's fibroblasts filtered through Sephadex G-150 as bound cobalamin, filtering just within the included volume of the gel (Fig. 1 propionate. These studies had indicated defective methionine synthesis from CH3-H4PteGlu and homocysteine, but normal succinate synthesis from methylmalonyl-CoA. These findings were consistent with the defective CH3-B,2 and normal Ado-B,2 observed in the patient's cells because of the requirement of these reactions for these cobalamins, respectively. Activity of methionine synthetase assayed in vitro in cell extracts was normal when the assay utilized conditions described for optimal activity (150 mM BME) (1). This is consistent with the normal cobalamin content of the methionine synthetase enzyme shown in Fig. 1 .
When concentrations of most reactants were varied under standard reducing conditions (150 mM BME), no difference was observed between the effect of such modifications on the enzyme activity in normal and the patient's cells. Reactants with similar sensitivity in affecting enzyme activity in normal and the patient's cells included CH3-H4PteGlu, S-adenosylmethionine (AdoMet), and CH3-B12. When the concentration of reducing agent in the reaction was altered, however, enzyme activity in the patient's extract became less than that of control extract at similar levels of reducing agent (Fig. 3) . The greatest difference between methionine synthetase activity in extracts of control and the patient's cells was observed at low concentrations of DTT. In addition to this greater requirement for DDT of methionine synthetase activity in patient's extracts than in control extracts, patient's extracts almost always generated more methionine synthetase activity in BME than in DTT, whereas the reverse was consistently observed in extracts of control cells. The ratio of methionine synthetase activity in 150 mM of BME to that in 25 mM DTT was 0.85±0.13 and 0.86±0.10 (x±SD, n = 3) in two control extracts and 1.45±0.26 (n = 4) in patient's extracts. At low concentration of BME or DTT, however, the methionine synthetase activity in extracts of control cells was always greater than that of the patient's cells. Methionine synthetase activity was thus consistently different in the patient's extracts from that in control extracts in that more activity was lost when reducing conditions were less stringent and in being more responsive to BME than to DTT as a reducing agent.
Effect ofmixing control and patient extracts on methionine synthetase activity. To determine if a factor other than methi- onine synthetase might be defective in extracts of patient's cells, methionine synthetase was analysed at 25 mM DTT (a concentration at which activity is maximal in normal but not patient's cells) in mixtures of normal and patient cells (Table  I) . Under these conditions, small quantities of extract from control cells were found to correct the methionine synthetase activity of mutant cells in excess of the methionine synthetase activity added from the normal extract. Mixing control and patient extract at 150 mM BME was only additive, and cobalamin C and D extract also corrected the defects in similar experiments at 10 mM DTT (data not shown). This indicates that the defect in the extracts of the patient's cells was not restricted to the methionine synthetase enzyme, but appeared due to the lack of an additional factor which corrected the activity of methionine synthetase in extracts of patient's cells.
Because it appeared that the intracellular defect related to reduction of cobalamin in patient cells, cells were incubated with different concentrations of DTT and '4C-labeled CH3-H4PteGlu and unlabeled OH-B12 to determine if this would affect the incorporation of labeled methyl into protein. Growth was inhibited at DTT concentrations in excess of 1 mM, but neither this concentration nor 10 or 20 mM DTT altered the incorporation of labeled methyl groups into normal or mutant cells, suggesting no effect on methionine synthetase within the cells. Growth of cells in the dark in 1.5 uM CH3-B12 in addition to 1 mM DTT did not improve incorporation of labeled methyl by cells from the patient despite chromatographic evidence that >90% of the extracellular cobalamin was CH3-B12 at the end of the incubation.
Effect ofnitrous oxide on methionine synthetase activity of cultured cells. The above studies indicated that whereas methionine synthetase activity in standard concentrations of thiols was normal in extracts of patient's cells, failure of the cells to synthesize adequate methionine for growth and their ,gM) of OH-B12 for 3 d, and at 18 h before the end of the incubation, culture bottles were gassed with 50% of nitrous oxide in oxygen. Holoenzyme activity of methionine synthetase activity (standard conditions) was reduced to <10% of control activity in extracts of control cells, whereas >75% of holoenzyme activity was retained by extracts of patient's cells (Fig.  4) . Apoenzyme activity (total holoenzyme) was not significantly affected by nitrous oxide exposure, indicating no effect of the gas on the enzyme itself. When fibroblasts were incubated for 3 d in labeled cobalamin with a source of transcobalamin II (human serum) and exposed to nitrous oxide for 18 h, '7Co-labeled CH3-B12 was reduced to 4-8% of total intracellular cobalamin in both control and patient's cells. In addition, directly exposing cell extracts to nitrous oxide for 1 min prior to assay resulted in a similar decrease in methionine synthetase specific activity by 40% in control and by 48% in patient's cells. This demonstrates that the proportion of methionine synthetase enzyme which was active corresponded to the proportion of CH3-Bl2 bound to it, and that in patient's cells, although the total proportion of the enzyme binding vitamin B,2 was similar to that in normal cells, only a minority of this bound cobalamin was CH3-B12, turned over intracellularly, and could be inhibited with nitrous oxide. The remainder of the enzyme-bound cobalamin could be activated in extracts in the presence of thiols, probably by conversion to B12r (Co'2). At concentrations of thiols used in the assay, solutions of OH-B12 could be shown to be converted to Bi2r (Co'2) within 10 min of adding DTT or BME. This strongly suggests that the majority of cobalamin bound to methionine synthetase in patient's cells was OH-B12 (Co+3) or OH2-B,2 (Co+3) since these forms would not be affected by nitrous oxide but would be activated in vitro by DTT or BME in the standard assay.
Discussion
Fibroblasts from this patient with homocystinuria and megaloblastic anemia in infancy were shown in a previous report (1) to incorporate labeled cobalamin in a normal fashion but to contain a smaller proportion of CH3-B12 than did normal cells. They were found to utilize CH3 from CH3-H4PteGlu less effectively than did normal cells. They differed from previously reported inherited defects of cobalamin metabolism (cobalamin C and D disease) in containing normal quantities of Ado-B12, in utilizing labeled propionate in a normal manner, and in having normal activity of methionine synthetase in cell extracts under standard assay conditions. Thus the defect in this child involves selectively the metabolism of CH3-B12 but not Ado-B12. This is supported by the failure of fibroblasts from the patient to grow in tissue culture medium in which homocysteine replaced methionine, even in the presence of excess B12. (12) . The normal sensitivity of the patient's methionine synthetase to inactivation by nitrous oxide in vitro and the decrease of intracellular methylcobalamin during incubation in nitrous oxide excludes an unusual enzyme configuration preventing access of the gas to the cobalamin. The correction of defective methionine synthesis in extracts of patient's cells by the addition of small quantities of normal extract suggests that the defect involves a step other than methionine synthetase, which might be related to the reduction of components during the enzyme reaction.
Methionine synthetase in Escherichia coli has been exten-
,.0
sively studied and appears to transfer a methyl group from 5-CH3H4PteGlu to B,2S(Co+') to form CH3-B,2 with subsequent methylation of homocysteine (13) . , 1
These studies suggest that in this patient there is an abnormality of methionine synthesis which can be demonstrated in cell extracts when these are assayed under conditions of limited reduction. The abnormality induces intracellular deficiency of methylcobalamin secondary to the defective enzyme activity. It is suggested that the defect is in a reducing system normally responsible for maintaining enzyme-bound cobalamin as B,21(Co+2). The defective molecule was excluded from Sephadex G-25 and thus probably is not unbound flavin or dinucleotide.
Cobalamin C and D cells, which have been assumed to be deficient in a cobalamin reductase activity (3), are defective in accumulating cobalamin from the surrounding medium in culture. Cells from the patient described here were not defective in accumulating cobalamin. If the cells of this patient were defective in a cobalamin reductase which reduces B,2.(Co"3) bound to methionine synthetase, but the putative reductase system deficient in cobalamin C and D cells were intact, one might explain this with the following hypothesis ( Fig. 5 ): It is probable that binding of cobalamin entering the cytoplasm to methionine synthetase is required to permit the accumulation of cobalamin by cells. If oxidized cobalamin entering the cytoplasm from lysozomes required reduction to bind to methionine synthetase, but once bound, could be oxidized without displacement from the enzyme, then cells defective in reductases acting on free cobalamin would not accumulate cobalamin effectively (cobalamins C and D); those with reductase defects affecting only the bound cobalamins (our patient) would accumulate B,2 normally, but would accumulate oxidized and thus unusable cobalamins during the course of intracellular metabolism. If so, intracellular cobalamin accumulation would require reduction of OH-B,2(CoI3) entering the lysosomes, and accumulation in our patient's cells would be expected to be normal. Once on the methionine synthetase, oxidation of reduced B,2(Co+2) to OH-B,2(CoI3) is not associated with the loss of cobalamin from bacterial enzyme (13) . In our patient, such reoxidized cobalamin would be available for methionine synthesis in cell extracts if reduced by thiols, but would not function within intact cells because of a putative deficiency of a reducing activity associated with methionine synthetase.
